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Abstract
 
B lymphocyte stimulator (BLyS) is a newly identified monocyte-specific TNF family cytokine.
 
It
 
 
 
has been implicated in the development of autoimmunity, and functions as a potent costimu-
lator with antiimmunoglobulin M in B cell proliferation in vitro. Here we demonstrate that
 
BLyS prominently enhances the humoral responses to both T cell–independent and T cell–
dependent antigens, primarily by attenuation of apoptosis as evidenced by the prolonged sur-
vival of antigen-activated B cells in vivo and in vitro. BLyS acts on primary splenic B cells au-
tonomously, and directly cooperates with CD40 ligand (CD40L) in B cell activation in vitro by
protecting replicating B cells from apoptosis. Moreover, although BLyS alone cannot activate
the cell cycle, it is sufficient to prolong
 
 
 
the survival of naive resting B cells in vitro. Attenuation
of apoptosis by BLyS correlates with changes in the ratios between Bcl-2 family proteins in fa-
vor of cell survival, predominantly by reducing the proapoptotic Bak and increasing its prosur-
 
vival partners, Bcl-2 and Bcl-xL. In either resting or CD40L-activated B cells, the NF-
 
k
 
B tran-
scription factors RelB and p50 are specifically activated, suggesting that they may mediate BLyS
signals for B cell survival. Together, these results provide direct evidence for BLyS enhance-
ment of
 
 
 
both T cell–independent and T cell–dependent humoral immune responses, and imply
a role for BLyS in the conservation of the B cell repertoire. The ability of BLyS to increase B
cell survival indiscriminately, at either a resting or activated state, and to cooperate with
CD40L, further suggests that attenuation of apoptosis underlies BLyS enhancement of
 
 
 
poly-
clonal autoimmunity as well as the physiologic humoral immune response.
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k
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Introduction
 
B lymphocyte stimulator (BLyS)
 
1
 
 (1), also called B cell acti-
vating factor belonging to the TNF family (BAFF [2]),
TNF homologue that activates apoptosis, nuclear factor
[NF]-
 
k
 
B, and c-Jun NH
 
2
 
-terminal kinase (THANK [3]),
TNF and apoptosis ligand–related leukocyte-expressed
ligand 1 (TALL-1 [4]), and zTNF4 (5) is a recent addition
to the TNF family. The expression of BLyS appears to be
regulated by IFN-
 
g
 
 and restricted to cells of myeloid origin
(1). BLyS has also been shown to bind only to mature B
cells (1, 2). This unique combination of cell specificity in
expression and targeting distinguishes BLyS from other
TNF family cytokines, and suggests a novel role for BLyS
in B cell immunity.
Consistent with this possibility, recombinant human
BLyS, in either the membrane-bound form or the soluble
form containing the extracellular 152 amino acids, func-
tions as a potent costimulator with anti-IgM for prolifera-
tion of tonsillar and peripheral blood B lymphocytes in
 
vitro
 
 
 
(1, 2). Moreover, intraperitoneal injection of soluble
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Abbreviations used in this paper:
 
 BCMA, B cell maturation antigen;
BLyS, B lymphocyte stimulator; DNP, 2,4-dinitrophenol; ELISPOT, en-
zyme-linked immunospot; EMSA, electrophoretic mobility shift assay;
HRP, horseradish peroxidase; NF, nuclear factor; TACI, transmembrane
activator and calcium modulator and cyclophilin ligand interactor;
TRAF, TNF receptor–associated factor. 
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human BLyS (1) or ectopic expression of BLyS in mice
(5–7) led to increases in B cells and plasma cells and eleva-
tion of serum Ig levels in the absence of immunization.
BLyS transgenic mice further developed severe autoim-
munity with characteristics of systemic lupus erythemato-
sus (5–7). Together, these results suggest that BLyS is a key
mediator of monocyte signals for the development of
polyclonal autoimmunity, and may contribute to the anti-
gen-specific antibody response. The humoral immune re-
sponse, in most cases, requires T cell help mediated by the
interaction between CD40, a TNF family receptor ex-
pressed on B cells, and CD40L, its ligand expressed on ac-
tivated T cells (8). Whether BLyS directly cooperates with
CD40L in the humoral immune response has not been
elucidated.
The mechanism of BLyS signaling is not well under-
stood. BLyS is a 285–amino acid type II transmembrane
protein, with significant homology to a proliferation-induc-
ing ligand (APRIL; 
 
.
 
25%), and to a lesser extent, TNF-
 
a
 
,
lymphotoxin 
 
a
 
, FasL, and TNF-related apoptosis-inducing
ligand (TRAIL), in its extracellular domain (1). Two pro-
teins that bind BLyS, transmembrane activator and calcium
modulator and cyclophilin ligand interactor (TACI) and B
cell maturation antigen (BCMA), have now been identified
(5, 9–11).
 
 
 
TACI was initially cloned as a TNF family pro-
tein expressed on the surface of B cells and ionomycin and
phorbol ester–activated T cells (12).
 
 
 
BCMA was previously
identified as an orphan TNF family protein (13), and was
only recently found to bind BLyS (5, 9).
 
 
 
Whereas nothing
is known about BCMA signaling, TACI appears to signal
as a classical TNF family receptor. The extracellular do-
main of TACI shares homology with death receptor 3 and
TNFR1, and its intracellular domain has been shown to as-
sociate with the calcium modulator and cyclophilin ligand
(CAML [12]), and to bind TNF receptor–associated factor
(TRAF)2, TRAF5, and TRAF6 in yeast two-hybrid
screens
 
 
 
(10).
 
 
 
Overexpression of TACI led to the activation
of NF-
 
k
 
B in 293 cells (11), and AP-1 and nuclear factor of
activated T cells in addition to NF-
 
k
 
B in transformed Jur-
kat T cells as determined by reporter assays (12). Likewise,
BLyS has been shown to activate NF-
 
k
 
B and c-Jun NH
 
2
 
-
terminal kinase in A20 lymphoma cells (10).
 
 
 
Although
these findings in cell lines implicate a role for NF-
 
k
 
B in
BLyS signaling, whether NF-
 
k
 
B is activated by BLyS in
primary B cells, the physiologic targets of BLyS action, is
not known.
To address these questions, we have investigated the role
of BLyS in T cell–independent and T cell–dependent anti-
body responses in vivo, and the cooperation between BLyS
and CD40L in the activation of primary mouse B cells in
vitro. Evidence is presented to suggest that attenuation of
apoptosis is the primary consequence of BLyS signaling in
B cells, which underlies the enhancement of humoral im-
mune response and is likely to be mediated by specific NF-
 
k
 
B and Bcl-2 family proteins. These findings have signifi-
cant implications for BLyS in the conservation of naive B
cells, in polyclonal autoimmunity, and in the physiologic
humoral immune response.
 
Materials and Methods
 
Immunization.
 
BALB/cAnNCR female mice, 6–8 wk of age,
were immunized with the indicated
 
 
 
amounts of the Pneumovax
23 vaccine (Merck) subcutaneously on days 0 and 7. Purified sol-
uble, recombinant human BLyS synthesized in baculovirus (20
 
m
 
g [1]) or PBS was administered subcutaneously daily through
day 9. The hapten carrier conjugate 2,4-dinitrophenol (DNP)-
BSA (100 
 
m
 
g) was administered intraperitoneally on days 0 and 7.
BLyS (20 
 
m
 
g) or PBS was administered intraperitoneally daily
through day 14. 4-hydroxy-3-nitrophenyl–chicken 
 
g 
 
globulin
(NP-CGG) was prepared by conjugating (4-hydroxy-3-nitro-
phenyl) acetyl succinimide ester (Biosearch Technologies, Inc.)
to chicken 
 
g 
 
globulin (Sigma-Aldrich) at an 18:1 ratio, as de-
scribed (14). C57BL/6 male mice, 10 wk of age, were immu-
nized intraperitoneally with 75 
 
m
 
g NP-CGG precipitated in a
100 mg/250 
 
m
 
l solution of aluminum hydroxide adjuvant.
 
 
 
BLyS
(10 
 
m
 
g) or PBS was administered intraperitoneally daily through
day 8. For each time point, three to five mice were used for each
experimental condition.
 
ELISA.
 
The relative titers of Pneumovax-specific polyclonal
IgM, IgA, and IgG were determined in sera collected on days 0
and 7 by ELISA on 96-well ELISA plates (Nunc)
 
 
 
coated over-
night at 4
 
8
 
C with 50 
 
m
 
l of Pneumovax (0.1 
 
m
 
g/ml) and blocked
with 100 
 
m
 
l of milk for 2 h at 4
 
8
 
C. Serum samples were serially
diluted (threefold) beginning with a 1:1,000 dilution across eight
wells of the 96-well plate. The blocking agent was removed and
the assay plates were washed twice with PBS. Diluted serum sam-
ples (100 
 
m
 
l) were added to individual wells and incubated at
room temperature for 1 h, after which plates were washed three
times with PBS and a biotinylated goat anti–mouse isotype-spe-
cific reagent added for 1 h at room temperature. Plates were
washed three times and developed using the ABC horseradish
peroxidase (HRP) kit (Vector Laboratories) and the appropriate
colorimetric substrate (3,3
 
9
 
,5,5
 
9
 
-tetramethylbenzidine). HRP re-
actions were stopped by the addition of dilute sulfuric acid. OD
readings at 414 nm were performed using a UV-MAX ELISA
reader (Molecular Devices). Data were analyzed using software
provided by Molecular Devices (SoftMax). Values are expressed
as relative titers corresponding to the highest reciprocal dilution
that yields a detectable signal in the assay. DNP-specific IgM and
IgG titers were assayed on sera collected on days 0, 7, and 14.
ELISA was performed similarly using plates previously coated
with 50 
 
m
 
l of DNP-KLH (100 
 
m
 
g/ml).
NP-specific IgM and IgG titers were assayed on sera collected
on days 0 and 8. ELISA plates (Corning) were coated overnight
at 4
 
8
 
C with 100 
 
m
 
l/well of a 100 
 
m
 
g/ml solution of 4-hydroxy-
3-iodo-5-nitrophenylacetyl succinimide ester conjugated to BSA
(NIP-BSA) in Tris-buffered saline (TBS: 20 mM Tris, pH 7.5,
150 mM NaCl). Serial dilutions of the serum were incubated
in triplicate on the NIP-BSA–coated ELISA plates at 4
 
8
 
C over-
night. Bound antibody was detected by sequential incubation
with biotinylated affinity-purified goat anti–mouse IgG or IgM
(1:30,000 dilution in 0.5% BSA/TBS; Southern Biotechnol-
ogy Associates, Inc.) for 2 h at 37
 
8
 
C, followed by a 30-min incuba-
tion with peroxidase-conjugated streptavidin at room temperature
(1:2,000 dilution in 0.5% BSA/0.05% Tween/TBS; Vector Lab-
oratories). The ELISAs were subsequently developed with an HRP
substrate kit (Bio-Rad Laboratories), detected at OD 414 nm on
a Titertek Multiskan II, and values were reported as described
above.
 
Enzyme-linked Immunospot.
 
Enzyme-linked immunospot
(ELISPOT) was used to quantify the number of plasma cells that
were secreting NP-specific IgM or IgG at the single cell level. 
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Multiscreen-HA membrane plates (Millipore) were coated with
50 
 
m
 
g/ml NIP-BSA overnight. Threefold serial dilutions begin-
ning with a 100-
 
m
 
l suspension of 10
 
7
 
 B cells per ml were
 
 
 
then
cultured on precoated HA-multiscreen membrane plates for 3.5 h
in complete RPMI at 37
 
8
 
C in a 5% CO
 
2 
 
chamber. Bound IgG or
IgM was detected by sequential incubation with biotinylated af-
finity-purified goat anti–mouse IgG or IgM (1:20,000 dilution in
PBS, 0.1% Tween, 5% FCS) and peroxidase-conjugated strepta-
vidin (1:1,000 dilution in PBS,
 
 
 
0.1%
 
 
 
Tween, 5% FCS). Secreting
cells were detected using 3-amino-9-ethyl-carbazole tablets
(AEC; Sigma-Aldrich) and counted in duplicate.
 
In Vitro
 
 
 
Primary B Cell Differentiation Assay.
 
Primary B cells
were isolated from spleens of 8–12-week-old C57BL/6 mice
(Taconic Farms). Splenocytes were depleted of red blood cells
with ACK lysis buffer (150 mM ammonium chloride, 6 mM cal-
cium bicarbonate, and 10 
 
m
 
M disodium ethylene diamine tet-
raacetic acid; all from BioWhittaker) and then incubated with
rabbit complement (Cedarlane) together with anti-Thy1.2 (hy-
bridoma HO-13-4) and anti-CD4 (hybridoma GK1.5) at 37
 
8
 
C
for 20 min to deplete macrophages and T lymphocytes. Discon-
tinuous Percoll
 
 
 
(1.129 g/ml; Amersham Pharmacia Biotech) den-
sity centrifugation was performed to recover resting B cells at the
60–70% interface (high density)
 
 
 
and activated B cells and plasma
cells at the 50–60% interface (low density). The resting B cells
(1.5 
 
3
 
 10
 
5
 
/ml) were cultured with mitomycin C (100 
 
m
 
g/ml)–
arrested CD40L-expressing L cells (CD40L cells) at a 10:1 ratio
unless otherwise specified, in RPMI 1640 (BioWhittaker) sup-
plemented with 10% heat-inactivated fetal bovine serum (Hy-
clone), 2 mM 
 
l
 
-glutamine, penicillin (100 U/ml), streptomycin
(100 U/ml), 2 mM nonessential amino acids, and 50 
 
m
 
M 
 
b
 
-mer-
captoethanol. The feeder layer in cocultures was renewed every
3 d. The stock of CD40L cells was cultured in the same media
without 
 
b
 
-mercaptoethanol and supplemented with HAT (0.1
mM hypoxanthine, 4 
 
3
 
 10
 
2
 
4
 
 mM aminopterin, and 1.8 
 
3
 
 10
 
2
 
2
 
mM thymidine; Sigma-Aldrich). Purified recombinant human
soluble BLyS was expressed in baculovirus and purified from Sf9
cell supernatant (1). The number of live cells was determined by
trypan blue
 
 
 
staining and cell counting in triplicate.
 
Detection of Surface CD40 and Fas and Intracellular IgM.
 
The
surface expression of CD40 and Fas was detected with a PE-con-
jugated rat
 
 
 
monoclonal antibody to CD40 and PE-conjugated
hamster monoclonal antibody to Fas (BD PharMingen) by flow
cytometry using a Becton Dickinson FACSCalibur™. A PE-
conjugated rat anti–mouse CD4 (BD PharMingen) was used as
an isotype control. Detection of intracellular IgM by immunoflu-
orescence
 
 
 
staining was performed essentially as described (15),
with a Texas red–conjugated goat anti–mouse IgM polyclonal
antibody (Southern Biotechnology Associates, Inc.). The cells
were counterstained for 4,6-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich) to localize the nuclei before microscopic analysis.
 
Annexin V Binding Assay.
 
The binding of annexin V to cell
surface phosphatidylserine was assayed on live cells enriched by
Ficoll (Amersham Pharmacia Biotech) centrifugation, using an
annexin V–FITC apoptosis detection kit (Oncogene Research
Products). Samples were analyzed with a FACSCalibur™ accord-
ing to the manufacturer’s specifications.
 
Cell Cycle Analysis.
 
Cell cycle analysis was performed on 1–3 
 
3
 
10
 
6
 
 live cells enriched by Ficoll centrifugation. The cells were
fixed in 70% ethanol at 4
 
8
 
C overnight, and incubated in 1 ml of
PBS containing 50 
 
m
 
g/ml propidium iodide (Sigma-Aldrich) and
100 U/ml ribonuclease A (Sigma-Aldrich) for 30 min at room
temperature in the dark. The total DNA content of each cell
 
 
 
was
analyzed with a FACSCalibur™ using a Cell-Fit program with
 
gating set to exclude debris and cells containing less than diploid
DNA. Each determination was based on the analysis of 10,000
cells.
 
 To detect replicating DNA, cells were cultured in the pres-
ence of 5 mM of 5-bromo-29-deoxyuridine (BrdU; Sigma-
Aldrich) for 2 h before fixation with 70% ethanol as described
above. The fixed cells were resuspended in a solution containing
2 N HCl and 0.5% Triton X-100 for 30 min at room temperature,
and neutralized in 0.1 M Na2B4O7, pH 8.5. Cells were then
washed with PBS containing 5% fetal bovine serum and 0.5%
Tween 20, and stained with a mouse FITC-conjugated anti-
BrdU monoclonal antibody (Boehringer) at a dilution of 1:50 for
30 min. The stained cells were resuspended in 1 ml of PBS con-
taining 5 mg/ml propidium iodide for 2 h and analyzed by FACS-
Calibur™ as described above.
Electrophoretic Mobility Shift Assays. To prepare whole cell ex-
tracts, viable cells were purified by Ficoll gradient, washed, and
resuspended in buffer A (20 mM Hepes, pH 7.9, 350 mM NaCl,
20% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA,
1% NP-40, 1 mM dithiothreitol, 0.4 mM Pefabloc, and 1 mg/ml
each of leupeptin, aprotinin, and pepstatin). After incubation on
ice for 10 min and clearing by centrifugation at 14,000 rpm for 10
min at 48C, the supernatant was collected and protein concentra-
tion was determined by the Bradford assay (Bio-Rad Laborato-
ries). Electrophoretic mobility shift assays (EMSAs) were per-
formed essentially as described previously (16), using 2.6 mg of
protein in each reaction. The NF-kB subunits in the DNA–pro-
tein complexes were identified by preincubating extracts with 0.8
ml of polyclonal antisera against NF-kB p50, p52, p65, crel, or
RelB (Santa Cruz Biotechnology, Inc.) for 1 h at 48C before the
addition of 20,000 cpm of 32P-labeled H2K probe (59-GATC-
CAGGGCTGGGGATTCCCCATCTCCACAGG-39). The
samples were resolved by electrophoresis on a native 5% poly-
acrylamide gel in 0.53 TBE (25 mM Tris-Cl, pH 8.3, 25 mM
boric acid, and 0.5 mM EDTA) at 200 V, and the gel was dried
and autoradiographed.
Immunoblotting. Proteins (15–40 mg, in equal amounts) in
whole cell extracts were resolved by electrophoresis on a 12%
polyacrylamide-SDS gel, transferred to a polyvinylidine difluoride
membrane  (PVDF; Millipore), and probed with the following
antisera: hamster anti–mouse Bcl-2, rabbit anti–human Bcl-xL,
and rabbit anti–human Bak (BD PharMingen). The blots were
subsequently incubated with specific biotinylated secondary anti-
bodies, followed by streptavidin-conjugated HRP (Jackson Im-
munoResearch Laboratories). The blots were developed by en-
hanced chemiluminescence (Amersham Pharmacia Biotech).
Results
BLyS Enhances the T Cell–independent Humoral Immune
Response. BLyS increases the serum Ig levels in the ab-
sence of immunization and functions as a potent costimula-
tor with anti-IgM for B cell proliferation in vitro, suggest-
ing that it may modulate the humoral immune response
independent of T cells. To address this possibility, whether
BLyS modulates the antigen-specific antibody response was
investigated in mice challenged with the Pneumovax 23
vaccine, a polyvalent vaccine consisting of highly purified
capsular polysaccharides from the 23 most prevalent or in-
vasive pneumococcal types of Streptococcus pneumoniae.
The serum titers of Pneumovax-specific IgM increased
z10-fold within 7 d of antigen injection (10, 1, or 0.1 mg/956 BLyS Attenuation of B Cell Apoptosis in the Humoral Immune Response
kg), consistent with an IgM-dominant response to a carbo-
hydrate antigen (Fig. 1 A). Coadministration of recombi-
nant soluble human BLyS (20 mg [1]) increased the mean
IgM titers 3–10-fold (Student’s one-tailed t test: P , 0.05;
Fig. 1 A), which were maintained for at least 14 d despite
discontinuation of BLyS on day 10, and were not signifi-
cantly increased by a secondary challenge on day 8 (data
not shown). As predicted from a T cell–independent anti-
gen, Pneumovax did not elicit a strong IgG response, and
the small increases observed were insensitive to simulta-
neous BLyS exposure (Fig. 1 B). By contrast, BLyS pro-
foundly increased IgA titers, 1,000–10,000-fold at day 7
over that of buffer and Pneumovax-only control groups
(P , 0.05). The frequency of antigen response also increased,
from 2 out of 15 for the Pneumovax-only group to 11 out
of 15 for mice injected with BLyS (Fig. 1 C). BLyS there-
fore enhances the humoral immune response of the IgM
and IgA isotypes to the T cell–independent polysaccharide
antigens contained in a Pneumovax vaccine.
BLyS Enhances the T Cell–dependent Humoral Immune Re-
sponse by Increasing Antigen-specific Plasma Cells. To inves-
tigate whether BLyS also enhances the T cell–dependent
humoral immune response, mice were challenged with the
hapten carrier DNP-BSA. Little if any DNP-specific IgM
was detected in mice immunized with the antigen only,
even on day 14 (Fig. 2 A), consistent with previously ob-
served DNP responsiveness among normal BALB/c mice
(data not shown). BLyS treatment alone led to a similarly
modest IgM response to DNP, most likely due to increases
in nonspecific antibody production (1). However, BLyS
(20 mg/mouse) markedly increased the relative titers of
serum DNP-specific IgM (5–10-fold) in immunized mice
(P , 0.05; Fig. 2 A). The relative titers of DNP-specific
IgG were increased by either immunization (30-fold) or BLyS
treatment (3-fold) by day 14, but not substantially by coad-
ministration with BLyS and DNP-BSA (2-fold; Fig. 2 A).
Thus, BLyS markedly enhances the IgM response, and
modestly increases the already robust IgG response, to
DNP–BSA.
To corroborate these findings, whether BLyS modulates
the antibody response to another well-characterized T cell–
dependent antigen, NP-CGG (14), was investigated. Com-
pared with PBS treatment, BLyS (10 mg/mouse) increased
the relative titers of NP-specific serum IgM twofold (P ,
0.05) and IgG fourfold (P , 0.05) by day 8 (Fig. 2 B). The
BLyS enhancement of antibody response to NP-CGG dif-
fered significantly from that to DNP-BSA, presumably due
to the nature of antigen, the difference in mouse strain, the
concentration of BLyS, and the time of serum collection in
this study. Despite these differences, BLyS enhances the hu-
moral immune response to two T cell–dependent antigens.
To determine whether BLyS enhances the antibody re-
sponse by increasing Ig-secreting cells, the number of
splenic B cells secreting NP-specific IgM or IgG was quan-
tified by ELISPOT, which assays Ig secretion at the single
cell level (Fig. 2 C). BLyS reproducibly increased the fre-
quency of NP-specific IgM and IgG plasma cells (twofold)
by day 8 (Fig. 2 C, left). Taking into account the expansion
of splenic B cells (see Fig. 3 B), this corresponded to a six-
fold increase in the total number of plasma cells secreting
NP-specific IgM and IgG (P , 0.05; Fig. 2 C, right). The
enhancement of NP-specific antibody response by BLyS
therefore has its basis in increases of antigen-specific, Ig-
secreting plasma cells.
BLyS Attenuates B Cell Apoptosis in a Primary T Cell–
dependent Response. Having shown that BLyS increased the
frequency and the total number of  NP-specific plasma
cells, we next asked whether this was due to prolonged cell
survival in vivo and in vitro. Immunization with NP-CGG
alone resulted in a small increase in the spleen weight (data
not shown), which was augmented by the administration
of BLyS (P , 0.05; Fig. 3 A). This corresponded to a 2.7-
fold increase (P , 0.05) by day 8 of total B cells isolated by
Percoll gradient centrifugation (Fig. 3 B).
The possibility that BLyS enhances B cell accumulation
by protection from apoptosis was then considered. Chro-
matin fragmentation, a signature of apoptosis in transformed
Figure 1. BLyS enhances antibody response to Pneumovax. Primary
Pneumovax 23–specific IgM (A), IgG (B), or IgA (C) responses in mice
after BLyS administration. Pneumovax-specific Ig titers were determined
by ELISA on sera collected from buffer control mice on day 0 (n), from
mice immunized with Pneumovax (s), or from mice immunized with
Pneumovax and injected subcutaneously daily with BLyS (20 mg/mouse)
on day 7 (d).957 Do et al.
cells and Fas-mediated apoptosis of B cells, is not often asso-
ciated with apoptosis of plasma cells or primary mouse B
cells (reference 17 and Chen-Kiang, S., manuscript in prep-
aration). We therefore chose to directly assay Annexin V
binding activity, which detects the translocation of phos-
phatidylserine from the inner to outer leaflet of the plasma
membrane characteristic of early apoptotic cells (17, 18).
Exposure to BLyS in vivo reduced apoptosis of both high
(60–70% interface) and low density (50–60% interface)
splenic B cells isolated from NP-CGG–immunized mice, in
particular the low density B cells (Fig. 3 C). Because these
cells exhibit a lower nuclear to cytoplasmic ratio character-
Figure 2. BLyS enhances antibody response to
DNP-BSA and  NP-CGG. (A) Primary DNP-BSA–
specific IgM and IgG responses in mice after BLyS ad-
ministration. Serum DNP–specific Ig titers were deter-
mined on day 14 by ELISA from PBS control mice
(n), DNP-BSA–immunized (s), BLyS alone (m) or
DNP-BSA–immunized and injected intraperitoneally
daily with 20 mg/mouse BLyS (d). (B) Primary NP-
CGG IgM and IgG responses in mice after BLyS ad-
ministration. NP-specific Ig titers were determined by
ELISA from sera collected from uninjected mice on
day 0 (s), or from NP-CGG–immunized mice on day
8, which were coinjected with PBS (s) or 10 mg/
mouse BLyS (d). (C) Primary NP-CGG–specific
IgM- and IgG-secreting plasma cells after PBS (P) or
BLyS (B) administration were determined by
ELISPOT assay on day 8. Frequency of plasma cells
(left) and total splenic plasma cells (right). These exper-
iments have been performed three times.
Figure 3. BLyS enhances activated B cell expansion
and reduces apoptosis in vivo and in vitro. (A) Spleens
were weighed (weights shown in grams) on day 8 of
NP-CGG immunization, with coinjection of PBS (s)
or 10 mg/mouse BLyS (d). (B) Viable splenic B cells
in PBS and BLyS–coinjected mice were determined on
day 8 of NP-CGG immunization (n 5 3). (C) Annexin
V binding of high density (H) and  low density (L)
splenic B cells isolated on day 11 after immunization
with NP-CGG and coinjected with PBS (s) or 10
mg/mouse BLyS (d) (n = 3). (D) Annexin V binding
of low density splenic B cells were isolated on day 8 of
NP-CGG–immunized mice, coinjected with PBS or
BLyS as indicated, and cultured in vitro for 24 h in me-
dia alone (s) or with 100 ng/ml BLyS, n 5 3 (d). (E)
Expression of CD40 and Fas on high (H) and low den-
sity (L) B cells without immunization (C), or on day 8
after immunization with NP-CGG coinjected with
PBS or BLyS. These experiments have been performed
three times.958 BLyS Attenuation of B Cell Apoptosis in the Humoral Immune Response
istic of activated B cells, these results suggest that BLyS pro-
tects activated B cells more effectively, presumably due to
their higher propensity to undergo apoptosis. To confirm
this finding, low density B cells were isolated from immu-
nized mice with BLyS or PBS treatment in vivo and incu-
bated in the presence or absence of BLyS for an additional
24 h in vitro. BLyS (100 mg/ml) significantly reduced apop-
tosis (25%) in B cells without prior exposure to BLyS (P ,
0.05; Fig. 3 D). Although B cells isolated from BLyS-
treated mice were less apoptotic, as expected, they were
further protected from apoptosis by the addition of BLyS in
vitro (P , 0.05; Fig. 3 D). BLyS therefore attenuates apop-
tosis of antigen-activated B cells in a primary T cell–depen-
dent immune response in vivo and in vitro.
Survival of activated B cells can be enhanced by CD40,
which signals cell survival and cell cycle activation, and re-
duced by Fas, which initiates apoptosis. This raises the pos-
sibility that reduction of apoptosis and enhancement of B
cell expansion might be secondary to regulation of CD40
or Fas expression by BLyS. However, this is not the case.
The expression of CD40 on B cells remained unchanged
after immunization and BLyS treatment. Whereas a slight
increase in Fas expression on low density B cells was seen
after immunization, Fas expression remained constant after
BLyS treatment (Fig. 3 E). These results rule out the possi-
bility that BLyS attenuates B cell apoptosis through increas-
ing CD40 or decreasing Fas expression.
BLyS Enhances B Cell Activation and Expansion in Response
to CD40L In Vitro. The marked increases in NP-specific
serum IgM and IgG titers and the corresponding plasma
cells secreting NP-specific Igs (Fig. 2) suggest that BLyS
enhances the T cell–dependent humoral immune response
by cooperating with CD40L early in B cell activation. This
possibility was investigated in vitro in primary resting
mouse splenic B cells cocultured with mitotically-arrested
CD40L cells at a 10:1 ratio. Under these conditions, .80%
of the resting B cells enter the cell cycle and expand within
36 h. The addition of BLyS (50 ng/ml) profoundly en-
hanced the expansion of live cells, fivefold by day 6 com-
pared with activation by CD40L alone (Fig. 4 A). This en-
hancement was BLyS concentration dependent, being
optimal between 1 and 10 ng/ml by day 3 (Fig. 4 B). Al-
though the basis for the decline in B cell expansion at
higher BLyS concentrations remains to be determined,
BLyS efficiently cooperates with CD40L in B cell activa-
tion in vitro.
Flow cytometric analysis of the cell cycle (17) showed
that BLyS increased the number of cells (24–33%) in the S
and G2/M phases of the cell cycle, which represent cycling
cells (19) (Fig. 4 C). To corroborate this result, the uptake
of BrdU into replicating DNA was determined by pulse-
labeling cells for 2 h at 12-h intervals (Fig. 4 D). The pres-
ence of BLyS prominently increased the number of repli-
cating cells (BrdU-positive), from twofold (1.5–3%) at the
onset of cell cycle entry at 36 h to fivefold (4.6–24%) at 60 h
during active replication. BLyS therefore enhances the acti-
vation and expansion of B cells in response to CD40L by
profound increases in replicating cells.
Attenuation of Apoptosis Underlies Cooperation of BLyS with
CD40L in B Cell Activation. The increase in replicating
cells was not accompanied by either accelerated cell cycle
entry, which occurs 24 h after CD40L activation (Fig. 4
D), or shortening of the cell cycle time as determined by
BrdU pulse–chase analysis (data not shown). This, together
with the marked reduction of apoptosis in activated B cells
in response to BLyS in vivo and in vitro (Fig. 3, C and D),
strongly suggests that the enhancement of B cell expansion
is secondary to protection of replicating B cells from apop-
tosis. This hypothesis further predicts that attenuation of B
cell apoptosis by BLyS and by CD40L may be functionally
redundant.
To address this possibility, resting B cells were activated
with increasing concentrations of CD40L by varying the
ratio of CD40L cells to B cells (Fig. 5 A). The expansion of
live cells, although evident only at the highest CD40L to B
cell ratio (1:1) on day 3, was prominently increased by co-
stimulation with BLyS (5 ng/ml; Fig. 5 A, left). Con-
versely, although protection of B cells from apoptosis by
CD40L was concentration dependent, the presence of
BLyS effectively reduced cell death even at the lowest
CD40L concentration, as determined by trypan blue stain-
ing (Fig. 5 A, right). Together with marked increases in
BrdU uptake (Fig. 4 D), these results suggest that BLyS co-
Figure 4. BLyS enhances the activation of B cells by CD40L in vitro.
(A) Resting mouse splenic B cells were cocultured with CD40L cells, in
the presence (d) or absence (s) of BLyS (50 ng/ml). The accumulation
of live cells was determined on the days indicated, by trypan blue staining
and counting in triplicate. This experiment has been performed three
times. (B) The accumulation of viable cell number on day 3 of coculture
with CD40L cells in the presence of indicated concentrations of BLyS or
without BLyS (N). (C) FACS® analysis of DNA content on day 3 of co-
culture with CD40L cells in the presence of indicated concentrations of
BLyS or without BLyS (N), and expressed as the percentage of cells in the
S and G2/M phases of the cell cycle. (D) Analysis of BrdU incorporation
in a 2-h period, at 12-h intervals of coculturing with CD40L cells in the
presence (d) or absence (s) of BLyS (5 ng/ml).959 Do et al.
operates with CD40L in B cells primarily by attenuation of
apoptosis, which is amplified by cell replication, leading to
augmented B cell expansion.
Analysis of annexin V binding activity confirmed that in-
creased expansion of live cells corresponded to reduced ap-
optosis by BLyS (Fig. 5 B). To further verify that attenua-
tion of apoptosis is the primary function of BLyS, the BLyS
and CD40L signals were uncoupled by removing CD40L
cells after 2 d of coculture. It was evident that BLyS signifi-
cantly protected CD40L-activated B cells from apoptosis
(Fig. 5 C). The lack of expansion of activated B cells after
CD40L removal further indicated that BLyS alone was in-
sufficient to sustain cell cycle progression. Consistent with
its inability to regulate CD40  or Fas  expression in vivo
(Fig. 3 E), BLyS did not alter the expression of CD40 or
Fas on CD40L-activated B cells in vitro (Fig. 6). These re-
sults confirm that attenuation of apoptosis underlies coop-
eration of BLyS with CD40L in B cell activation.
BLyS Significantly Prolongs the Survival of Naive Resting B
Cells. The reproducible, albeit modest, reduction in apop-
tosis of high density B cells in response to BLyS in vivo
(Fig. 3 C) suggests that attenuation of apoptosis by BLyS is
not restricted to B cells activated by antigen or CD40L. In-
deed, BLyS alone (5 ng/ml) significantly protected naive
resting splenic B cells from apoptosis, as evidenced by the
maintenance of live cells (from 20 to 75%) for 4 d in vitro
in the presence of BLyS and the corresponding decrease in
annexin V binding activity (Fig. 7 A). Attenuation of apop-
tosis by BLyS was not accompanied by cell cycle activation
(Fig. 7 B), consistent with failure of BLyS to sustain cell cy-
cle progression after CD40L activation (Fig. 5 C). More-
over, BLyS did not enhance IgM synthesis or induce ap-
preciable changes in cell morphology in either resting or
CD40L-activated B cells (Fig. 7 C). Thus, BLyS functions
to prolong the survival of naive resting B cells in addition
to CD40L-activated B cells in vitro.
BLyS Regulates Bcl-2 Family Proteins. The Bcl-2 family
proteins are differentially regulated in response to various
stimuli in B lymphocytes and are crucial for their survival
(20, 21). Given that BLyS effectively attenuates B cell apop-
tosis in either resting or activated states in vivo and in vitro,
it was of interest to determine whether BLyS regulates Bcl-2
family proteins. We addressed this question first in B cells
after NP-CGG immunization. Of the Bcl-2 family proteins
examined, BLyS reduced the expression of Bak modestly in
both high and low density B cells without changing the ex-
pression of its antiapoptotic partners, Bcl-xL or Bcl-2 (Fig.
8 A and data not shown).
Since BLyS attenuates B cell apoptosis independent of
antigen stimulation (Figs. 5 and 7), we then characterized
the regulation of Bcl-2 family proteins by BLyS and
CD40L in vitro. The expression of Bak was profoundly re-
duced by CD40L activation, and further diminished to un-
detectable levels by costimulation with BLyS (Fig. 8 B). Al-
though Bcl-xL was increased and Bcl-2 was reduced by
CD40L activation, as expected from their regulation (dur-
ing B cell activation) in germinal centers (22, 23), they
were differentially regulated by BLyS; Bcl-xL expression
Figure 5. BLyS enhances the expansion of
CD40L-activated B cells through the attenuation
of apoptosis. (A) The accumulation of live cells
and the percentage of  dead B cells were deter-
mined by trypan blue staining on days of culturing
with CD40L cells at the indicated ratios in the
presence (d) or absence (s) of BLyS (5 ng/ml).
(B) The accumulation of live cells and the percent-
age of cells expressing annexin V binding activity
were determined on B cells continuously cocul-
tured with CD40L cells at a ratio of 10:1, or (C)
cultured in media alone after 2 d of coculture with
CD40L cells, in the presence (d) or absence (s)
of BLyS (5 ng/ml). These experiments were re-
peated three times.
Figure 6. BLyS does not regulate CD40 or Fas expression in vitro.
FACS® analysis of CD40 and Fas expression on the indicated days of in
vitro culturing in the presence of CD40L, alone or together with BLyS (5
ng/ml). These experiments were repeated three times.960 BLyS Attenuation of B Cell Apoptosis in the Humoral Immune Response
was not modified, although Bcl-2 expression was partially
restored by BLyS costimulation (Fig. 8 B, compare lanes 1,
4, and 5). These results were similar but not identical to
those obtained from immunized B cells in vivo, possibly
due to the synchronized nature of the in vitro experiments
and the absence of antigen activation. Protection of
CD40L-activated B cells from apoptosis by BLyS therefore
correlates with inverse regulation of the pro- and antiapop-
totic proteins of the Bcl-2 family.
BLyS also protects naive resting B cells from apoptosis
(Fig. 8 B, lanes 1–3). However, the regulation of Bcl-2
family proteins in this population was different from that of
CD40L-activated B cells:  BLyS appreciably elevated the
expression of Bcl-2 and Bcl-xL without changing the ex-
pression of Bak. Taken together, these results suggest that
BLyS regulates the ratio of Bcl-2 family proteins to favor
cell survival in both resting and CD40L-activated B cells by
distinct mechanisms.
BLyS Preferentially Activates NF-kB RelB and p50 in Rest-
ing and Activated B Cells. TNF family proteins frequently
activate NF-kB and its downstream antiapoptotic genes
(24), including Bcl-xL (25–28). NF-kB has been shown to
be activated by BLyS or by overexpression of TACI in cell
lines (10, 11), and we have evidence that attenuation of ap-
optosis by BLyS correlated with regulation of Bcl-2 family
proteins (Fig. 8). Whether NF-kB was activated by BLyS
in primary B cells was then determined (Fig. 9).
In freshly isolated, resting naive splenic B cells, active
NF-kB binding complexes consisting of p50/crel, p50/
p65, p50/RelB, and p50/p50 dimers were already present,
as indicated by antibody interference analysis in EMSAs
(Fig. 9, A and B). Within 1 d of in vitro culturing, these
complexes were drastically reduced, correlating with apop-
tosis presumably due to loss of in vivo stimuli (Fig. 9 A,
lane 2). The NF-kB binding activity was sustained
throughout the 3 d of coculture with CD40L cells (Fig. 9,
A, lanes 3–8, and B, lanes 1–6). Costimulation with BLyS
(5 ng/ml) significantly increased the activation of all NF-
kB complexes, in particular the p50 homodimer, to three-
fold by day 3 compared with stimulation with CD40L
alone (Fig. 9, A, lanes 3–8, and B, lanes 7–12). BLyS there-
fore enhances NF-kB activation in primary B cells in coop-
eration with CD40L.
Because BLyS also prolongs the survival of resting cells
(Fig. 7), whether it could activate NF-kB in resting B cells
was examined. The NF-kB DNA binding activity present
in resting B cells was maintained for 1 h in vitro, but de-
clined by 2 h, and reached an extremely low level by 24 h
(Fig. 9 C, lanes 2, 4, and 6). BLyS not only prevented this
decline, but with time also enhanced the binding of p50/
RelB and p50/p50 dimers (Fig. 9 C, lanes 5–9). A notable
exception was p50/p65, whose binding was greatly re-
duced by 24 h and could not be restored by BLyS. Attenu-
ation of apoptosis in naive resting B cells by BLyS in vitro
therefore strikingly correlated with preservation of the in
vivo (0 h) NF-kB activity and the enhancement of p50/
RelB and p50/p50 activation. Together, these results pro-
vide direct evidence for activation of specific NF-kB sub-
units by BLyS in primary B cells independent of their acti-
Figure 7. BLyS prolongs the
survival of resting B cells in
vitro. (A) The number of live
resting B cells and the percentage
of cells expressing Annexin V
binding activity were deter-
mined on the days indicated dur-
ing culture in media in the pres-
ence (m) or absence (n) of BLyS
(5 ng/ml). (B) FACS® analysis of
DNA content of day 0 and 3 B
cells. (C) Immunostaining of in-
tracellular IgM in B cells cocul-
tured with CD40L cells or BLyS
(5 or 50 ng/ml), or both, on the
days indicated. These experi-
ments have been performed
three times.
Figure 8. Regulation of Bcl-2
family proteins by BLyS. (A) Ex-
pression of Bak and Bcl-xL in
high density (H) and low density
(L) splenic B cells isolated from
mice administered with BLyS or
PBS on day 11 of immunization
with NP-CGG. (B) Expression
of Bak, Bcl-xL, and Bcl-2 on
high density splenic B cells, ei-
ther freshly isolated (lane 1), after
24 h of in vitro culture with me-
dia alone (lanes 2 and 3), or after
48 h of coculture with CD40L
cells (lanes 4 and 5), in the pres-
ence or absence of BLyS. ns,
nonspecific bands used as con-
trols for sample loading.961 Do et al.
vation state, and suggest a role of NF-kB in the attenuation
of apoptosis signaled by BLyS.
Discussion
In summary, our results have demonstrated that BLyS
enhances the physiologic humoral immune response to
both T cell–independent and T cell–dependent antigens,
and strongly suggest that attenuation of B cell apoptosis is
the underlying mechanism.
Modulation of Physiologic Humoral Immune Response by BLyS
The ability of BLyS to augment antibody response to the
polyvalent carbohydrate vaccine Pneumovax demonstrates
that it can modulate the physiologic humoral immune re-
sponse independent of T cells (Fig. 1). Moreover, we show
that BLyS enhances the humoral immune response to two
T cell–dependent antigens, DNP-BSA and NP-CGG
(Figs. 2 and 3). While this manuscript was in review, it was
reported that the addition of a chimeric TACI–Fc blocked
the increase of serum anti-Pneumovax IgM (10), disrupted
germinal center formation, and inhibited antibody response
to NP-CGG (11) and to KLH (10). Although these reports
show that BLyS is a participant in the humoral immune re-
sponse, our results indicate that additional BLyS can en-
hance the magnitude of the response. Thus, these studies
complement each other and establish that BLyS modulates
both T cell–dependent and –independent humoral im-
mune responses.
We further showed that costimulation with BLyS in vivo
led to increased serum titers of antigen-specific Igs of the
IgM and IgA isotypes in response to Pneumovax, of pre-
dominantly  the IgM isotype against DNP-BSA, and of
both IgM and IgG against NP-CGG. The common de-
nominator of all three of these responses was an increase in
the IgM response, suggesting that BLyS acts early in the
humoral immune response. The characterization of the
NP-CGG response further demonstrates that the elevation
of antibody levels has its basis in the increase in antigen-
specific plasma cells, which in turn results from enhanced
expansion of activated splenic B cells in response to BLyS
(Fig. 3). Our findings provide a cellular basis for further in-
vestigation of BLyS response in humoral immunity. They
also leave open the temporal and spatial specificity of BLyS
action during B cell terminal differentiation. Is the in-
creased accumulation of NP-specific IgG plasma cells solely
a consequence of the prior expansion of NP-specific IgM
mediated by BLyS? Are B cells subject to BLyS regulation
after isotype switch or terminal differentiation to plasma
cells? Does BLyS increase the expansion of long-lived
plasma cells in the bone marrow? Elucidating the temporal
and spatial specificity of the BLyS response as well as the
regulation of the BLyS receptors during B cell terminal dif-
ferentiation would help to elucidate the modulation of the
humoral immune response by BLyS.
Cooperation between BLyS and CD40L
Reconstitution of BLyS action on primary B cells in vitro
demonstrates that BLyS acts on B cells autonomously, and
that it cooperates synergistically with CD40L in B cell acti-
vation and expansion (Figs. 4–7). The profound enhance-
ment of CD40L activation by BLyS further suggests a tri-
partite interaction between BLyS expressed on monocytes,
CD40L expressed on T cells, and CD40 and BLyS receptors
expressed on B cells. Although BLyS does not regulate ei-
ther CD40 or Fas expression on B cells (Fig. 6), it is possible
that interactions between BLyS and other TNF family pro-
teins expressed on T and B cells occur and can further con-
tribute to the modulation of B cell immune response.
Most importantly, our data strongly suggest that the pri-
mary functional consequence of cooperation between
BLyS and CD40L is enhanced expansion due to attenua-
tion of apoptosis, as determined by the relative contribu-
tions of BLyS to cell cycle progression and cell survival
(Figs. 4 and 5). On this basis, we suggest that BLyS signal-
ing lowers the B cell survival threshold, thereby leading to
Figure 9. BLyS activates NF-kB in resting and
CD40L-activated B cells. (A) EMSA of the NF-kB
DNA binding activity present in whole cell extracts
prepared from freshly isolated resting splenic mouse
B cells (0 d), cells cultured in media alone for 1 d
(lane 2), or on days of coculture with CD40L cells
in the presence or absence of 5 ng/ml BLyS. The
migration of specific NF-kB complexes is marked.
(B) EMSA of extracts prepared from B cells cocul-
tured with CD40L cells in the presence or absence
of BLyS (5 ng/ml) for 3 d, with or without prein-
cubation with indicated antibodies. (C) EMSA of
NF-kB DNA binding activity present in whole cell
extracts prepared from freshly isolated resting
splenic B cells (lane 1), or cultured for hours in me-
dia in the presence or absence of 100 ng/ml of
BLyS (lanes 2–9). RelB and p50 lanes represent
preincubation of extracts with the antibodies.962 BLyS Attenuation of B Cell Apoptosis in the Humoral Immune Response
augmented expansion of B cells after activation by CD40L
(see below). This understanding has profound implications
for the mechanism of BLyS action in physiologic T cell–
dependent antibody response.
Mechanism of BLyS Action in Primary B Cells
BLyS Attenuates B Cell Apoptosis. BLyS has been sug-
gested to enhance B cell proliferation based on enhanced
accumulation of activated B cells in germinal centers and
plasma cells in BLyS transgenic mice (6), and expansion of
anti-IgM stimulated B cells in response to BLyS in vitro
(1). Here we suggest that BLyS primarily enhances B cell
survival, which secondarily leads to greater accumulation of
replicating B cells. The evidence supporting this conclusion
is as follows. First, exposure to BLyS reduces apoptosis of
NP-CGG–immunized B cells in vivo and in vitro. Second,
BLyS prolongs the survival of B cells activated by CD40L
in vitro, even after removal of CD40L stimulation. Third,
BLyS prolongs the survival of naive resting B cells. Finally,
BLyS alone was incapable of activating the cell cycle. Con-
sistent with our conclusions, BLyS was reported to enhance
the survival of the heterogeneous splenocyte population in
vitro (9). Thus, BLyS amplifies the CD40L activation of B
cells by rescuing actively replicating cells which would oth-
erwise have been eliminated by apoptosis.
BLyS reduces apoptosis of naive resting B cells as well as
CD40L-activated B cells in the absence of exogenous death
signals, and does not enhance survival through activation of
CD40 or reduction of Fas expression in vivo and in vitro.
On this basis, BLyS is likely to antagonize an as yet uniden-
tified Fas-independent apoptotic pathway(s) operating in
primary resting and activated B cells.
Regulation of Bcl-2 Family Proteins by BLyS. In our first
attempt to elucidate the BLyS signaling pathway in primary
B cells, we have found that BLyS attenuation of apoptosis
correlates with changes in the ratio of Bcl-2 family proteins
to favor cell survival. In NP-CGG–challenged mice, BLyS
reduced the proapoptotic Bak protein without accompany-
ing changes in Bcl-2 or Bcl-xL in B cells. After CD40L ac-
tivation in vitro, BLyS prominently reduced Bak and par-
tially restored Bcl-2 expression. By contrast, Bcl-xL was
modestly, if at all, upregulated by BLyS alone in vitro (Fig.
8).  The Bcl-2 family proteins are therefore differentially
regulated in primary B cells in the context of immunization
and activation state. Bcl-2 is required for the survival of
mature naive lymphocytes (29), and Bcl-xL is crucial for
the survival of immature lymphocytes (30) and germinal
center B cells (23). The impairment in affinity maturation
of germinal center B cells in Bcl-xL transgenic mice (31),
and in negative selection of autoreactive B cells in Bcl-2
transgenic mice (32), further highlights the critical roles of
Bcl-2 family proteins in the humoral immune response.
The levels of Bcl-2 protein have been shown to be higher
in peripheral B cells isolated from BLyS transgenic mice
(6). Our results provide the first experimental evidence
correlating regulation of Bcl-2 family proteins in primary B
cells by BLyS with cell survival in vivo and in vitro. Al-
though preliminary, they are consistent with a role for Bcl-2
family proteins in mediating the BLyS survival signals in
the immune response (6).
Activation of NF-kB by BLyS. The sustained activation
of p50 and RelB by BLyS in naive resting B cells and
CD40L-activated B cells have provided the first evidence
for BLyS regulation of NF-kB in primary B cells (Fig. 9).
NF-kB subunits are thought to be differentially used in cell
cycle progression and apoptosis in resting and activated B
cells (33). Our finding of differential activation of NF-kB
subunits by BLyS is consistent with this notion. Although
p50 has not been shown to be essential for B cell survival, it
is required for basal and specific antibody response as sug-
gested by studies of p50-deficient mice (34). RelB is re-
quired for the development of specific dendritic cells (35)
and for macrophage-mediated immunity to various patho-
gens (36). The striking correlation between differential ac-
tivation of p50 and RelB by BLyS and attenuation of apop-
tosis implies that these NF-kB subunits specifically mediate
BLyS signals for B cell survival. In this regard, it is surpris-
ing that the p65/RelA dimer, which is associated with the
antiapoptotic effects of NF-kB in various systems (37), is
not activated by BLyS. Instead, RelB, which has not yet
been shown to have antiapoptotic properties in B cells, is
regulated by BLyS. Whether p50 or RelB is required to
mediate the BLyS signals for B cell survival in response to
BLyS is currently under investigation.
BLyS Attenuation of B Cell Apoptosis and Autoimmunity
Attenuation of apoptosis by BLyS is not restricted to B
cells after activation by antigen or CD40L, as BLyS also
prolongs the survival of high density B cells after antigen
challenge in vivo (data not shown) and naive resting B cells
in vitro (Fig. 7). Activation of the cell cycle is therefore not
required to prime the primary B cells for BLyS response.
This finding implies that BLyS may contribute to both the
conservation of the B cell repertoire and the development
of polyclonal autoimmune diseases. Consistent with this
notion, the addition of soluble BCMA-Ig reduced the total
number of B cells in the blood and the peripheral lymphoid
organs (9). The deletion or anergy of autoreactive B cells
prevents autoimmunity (38), and apoptosis of antigen-spe-
cific B cells after activation is crucial for the negative con-
trol of the humoral immune response (39). The develop-
ment of autoimmune disease in BLyS transgenic mice (5–7)
could be explained by our findings that BLyS enhances B
cell survival indiscriminately. This hypothesis is supported
by the finding that TACI–Fc can delay the onset of au-
toimmunity in at least one mouse model of systemic lupus
erythematosus (5). A better understanding of the mecha-
nism of BLyS signaling should facilitate the development of
BLyS as a specific target for control of the humoral im-
mune response and for therapeutic interventions of au-
toimmune diseases.
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